News LEO launches chronic hand eczema drug in its first market Germany has become the debut market for LEO Pharma's Anzupgo, the first topical treatment specifically approved for chronic hand eczema (CHE).
News LEO closes on first approval for chronic hand eczema drug Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.